Author

A. Kersbergen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Batrouney· 1 shared A. Gasparini· 1 shared A. Kucukosmanoglu· 1 shared C. Khoo· 1 shared G. Borst· 1 shared J. Jonkers· 1 shared J. Minna· 1 shared J. Ng· 1 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Batrouney

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Brief report: Reclassifying SCLC-Y as SMARCA4 deficient malignancies - resolving the controversy

J. Ng, L. Cai, L. Girard, O. Prall, N. Rajan, C. Khoo, A. Batrouney, A. Kersbergen, M. Christie, J. Minna, M. L. Burr, K. D. Sutherland

The paper reclassifies YAP1-expressing SCLC-Y as SMARCA4-deficient malignancies, showing they lack SCLC features and instead resemble SMARCA4-deficient tumors.

bioRxiv · Oct 9, 2022Cancer Biology

Radiosensitivity is an acquired vulnerability of PARPi-resistant BRCA1-deficient tumors

M. Barazas, A. Gasparini, Y. Huang, A. Kucukosmanoglu, S. Annunziato, P. Bouwman, W. Sol, A. Kersbergen, N. Proost, M. van de Ven, J. Jonkers, G. Borst, S. Rottenberg

This study identifies radiotherapy as a therapeutic target for BRCA1-deficient tumors that have developed resistance to PARP inhibitors through 53BP1 pathway inactivation.

bioRxiv · Jul 17, 2018Cancer Biology